Fieldview Capital Management LLC Invests $1.91 Million in Gilead Sciences, Inc. $GILD

Fieldview Capital Management LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 17,188 shares of the biopharmaceutical company’s stock, valued at approximately $1,908,000.

Other institutional investors have also recently bought and sold shares of the company. Corundum Trust Company INC bought a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $26,000. Howard Hughes Medical Institute bought a new position in shares of Gilead Sciences during the second quarter worth approximately $30,000. MTM Investment Management LLC grew its holdings in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 176 shares in the last quarter. Kilter Group LLC acquired a new stake in shares of Gilead Sciences during the second quarter worth $33,000. Finally, Millstone Evans Group LLC increased its position in Gilead Sciences by 58.7% during the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 118 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the sale, the chief executive officer owned 642,308 shares of the company’s stock, valued at approximately $92,999,775.32. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.43, for a total transaction of $463,290.00. Following the transaction, the chief financial officer owned 167,779 shares of the company’s stock, valued at $25,910,110.97. This trade represents a 1.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 309,280 shares of company stock worth $43,935,470. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $146.63 on Tuesday. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $182.03 billion, a PE ratio of 21.66, a price-to-earnings-growth ratio of 1.89 and a beta of 0.36. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The stock’s 50-day simple moving average is $138.73 and its 200 day simple moving average is $126.06.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is currently 46.68%.

Analysts Set New Price Targets

GILD has been the topic of a number of analyst reports. Daiwa Securities Group increased their price target on Gilead Sciences from $129.00 to $161.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. TD Cowen upped their price target on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Barclays assumed coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They set an “equal weight” rating and a $155.00 price target on the stock. Leerink Partners lifted their price objective on shares of Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Finally, Morgan Stanley boosted their price objective on shares of Gilead Sciences from $150.00 to $171.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Twenty-three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $156.72.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.